|Expense Ratio (net)||N/A|
|Last Cap Gain||N/A|
|Morningstar Risk Rating||N/A|
|Beta (5Y Monthly)||N/A|
|5y Average Return||N/A|
|Average for Category||N/A|
NEW YORK, NY / ACCESSWIRE / June 4, 2018 / Juan Monteverde , founder and managing partner at Monteverde & Associates PC , a national securities firm headquartered at the Empire State Building in New York ...
BALA CYNWYD, PA / ACCESSWIRE / May 16, 2018 / Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of ARMO Biosciences, Inc. ("ARMO" ...
BALA CYNWYD, PA / ACCESSWIRE / May 10, 2018 / Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of ARMO Biosciences, Inc. ("ARMO'' ...
The latest earnings release ARMO BioSciences Inc’s (NASDAQ:ARMO) announced in December 2017 indicated company earnings became less negative compared to the previous year’s level – great news for investors BelowRead More...
The deal between the two companies will have Eli Lilly acquiring ARMO Biosciences Inc for $50 per share. This represents a roughly 68% premium to ARMO stock’s closing price on Wednesday. The agreement between ARMO Biosciences Inc and Eli Lilly will have the latter making a tender offer of $50 per share for ARMO stock.
The markets may be volatile – but this hasn’t stopped IPOs. According to Renaissance Capital, the first quarter saw the largest amount raised by newly public companies since 2014. In all, 43 companies raised a hefty $15.6 billion.
ARMO Biosciences Inc (NASDAQ: ARMO )'s lead product candidate AM0010 is a drug for the treatment of pancreatic ductal adenocarcinoma recently showed "promising" data that's supportive of a potentially ...